share_log

Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP...

Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP...

美敦力宣佈其SPYRAL HTN-ON MED臨床試驗的長期數據顯示,接受Symplicity Spyral腎臟脫神經系統射頻腎臟脫神經治療的受試者在24小時動態動脈壓平均值和收縮壓方面有更大的降低……
Benzinga ·  10/29 02:23

Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP Compared To Sham Patients At 2-Years

美敦力宣佈其SPYRAL HTN-ON MED臨床試驗的長期數據顯示,在接受Symplicity Spyral腎臟射頻消融系統射頻腎臟消融的受試者在2年內比安慰組患者在24小時動態動脈血壓監測和辦公室收縮壓方面有更大的降低。

Company commits to advancing clinical data for Symplicity with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial

公司致力於推動Symplicity的臨床數據,通過SPYRAL Gemini臨床試驗以及GSR-DEFINE臨床試驗的擴大。

GALWAY, Ireland and WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT).

愛爾蘭戈爾韋和華盛頓,2024年10月28日 / PRNewswire / - 全球衛生保健科技領導者美敦力plc(NYSE:MDT)今天宣佈了來自其SPYRAL HTN-ON MED臨床試驗的新的長期數據,顯示接受Symplicity Spyral腎臟消融(RDN)系統射頻腎臟消融的受試者在兩年內24小時動態收縮血壓(ABPM)和辦公室收縮血壓(OSBP)方面的降壓明顯大於安慰組患者。這些數據作爲2024年經皮血管介入心臟治療學會議(TCT)的一部分進行了介紹。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論